MEDICURE INCORPORATED (OTCMKTS:MCUJF) Stock Is Shorted More

February 15, 2018 - By Adrian Mccoy

The stock of MEDICURE INCORPORATED (OTCMKTS:MCUJF) registered an increase of 22.58% in short interest. MCUJF’s total short interest was 3,800 shares in February as published by FINRA. Its up 22.58% from 3,100 shares, reported previously. With 1,300 shares average volume, it will take short sellers 3 days to cover their MCUJF’s short positions.

It closed at $5.82 lastly. It is down 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Medicure Inc., a specialty pharmaceutical company, engages in the research, clinical development, and commercialization of human therapeutics in Canada, the United States, Barbados, and India. The company has market cap of $90.86 million. The firm primarily markets and sells AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction, as well as AGGRASTAT high-dose bolus regimen for the reduction of thrombotic cardiovascular events in patients with non-ST elevated acute coronary syndrome. It has a 8.24 P/E ratio. It is also developing TARDOXAL that is in Phase IIa clinical trials for the treatment of tardive dyskinesia/neurological indications.

More important recent Medicure Inc. (OTCMKTS:MCUJF) news were published by: Seekingalpha.com which released: “Undervalued And Underfollowed; Medicure Is My Favorite Pharma Small Cap” on February 17, 2016, also Marketwatch.com published article titled: “Medicure Inc.”, Businesswire.com published: “Medicure Acquires License to Sell and Market PREXXARTAN” on October 31, 2017. More interesting news about Medicure Inc. (OTCMKTS:MCUJF) was released by: Nasdaq.com and their article: “Is Medicure Inc. (MCUJF) a Great Stock for Value Investors?” with publication date: September 20, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.